Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q4 2020 · 10-K
Revenue$20.61M$20.61M−41.3% vs Q4 2019 Net Income-$62.28M-$62.28MN/M vs Q4 2019 EPS Diluted-$0.68-$0.68N/M vs Q4 2019 Gross Profit$11,213,000−41.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Operating Cash Flowderived-$52,554,000N/M Free Cash Flowderived-$55,048,000N/M Margins · derivedGross margin54.4%−0.3 pt vs Q4 2019
Operating margin-297.5%−128.3 pt vs Q4 2019
Net margin-302.3%−137.2 pt vs Q4 2019
ended Dec 31, 2020 · filed Feb 24, 2021 · 55 d after period end